TSLPR: A new CAR in the showroom for B-ALL

David Marc Davies; John Maher

doi:10.1182/blood-2015-06-650812

TSLPR: A new CAR in the showroom for B-ALL

David Marc Davies, John Maher

Research output: Contribution to journal › Article › peer-review

5 Citations (Scopus)

Abstract

In this issue of Blood, Qin et al demonstrate the ability of chimeric antigen receptor (CAR)-engineered T cells targeted against thymic stromal lymphopoietin receptor (TSLPR) to eradicate disease in several models of B-cell acute lymphoblastic leukemia (B-ALL) that overexpress this protein.

Original language	English
Pages (from-to)	567-569
Number of pages	3
Journal	Blood
Volume	126
Issue number	5
DOIs	https://doi.org/10.1182/blood-2015-06-650812
Publication status	Published - 30 Jul 2015

Access to Document

10.1182/blood-2015-06-650812

Cite this

@article{87b04a1b509d46bf845c002f72541518,

title = "TSLPR: A new CAR in the showroom for B-ALL",

abstract = "In this issue of Blood, Qin et al demonstrate the ability of chimeric antigen receptor (CAR)-engineered T cells targeted against thymic stromal lymphopoietin receptor (TSLPR) to eradicate disease in several models of B-cell acute lymphoblastic leukemia (B-ALL) that overexpress this protein.",

author = "Davies, {David Marc} and John Maher",

year = "2015",

month = jul,

day = "30",

doi = "10.1182/blood-2015-06-650812",

language = "English",

volume = "126",

pages = "567--569",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "5",

}

TY - JOUR

T1 - TSLPR

T2 - A new CAR in the showroom for B-ALL

AU - Davies, David Marc

AU - Maher, John

PY - 2015/7/30

Y1 - 2015/7/30

N2 - In this issue of Blood, Qin et al demonstrate the ability of chimeric antigen receptor (CAR)-engineered T cells targeted against thymic stromal lymphopoietin receptor (TSLPR) to eradicate disease in several models of B-cell acute lymphoblastic leukemia (B-ALL) that overexpress this protein.

AB - In this issue of Blood, Qin et al demonstrate the ability of chimeric antigen receptor (CAR)-engineered T cells targeted against thymic stromal lymphopoietin receptor (TSLPR) to eradicate disease in several models of B-cell acute lymphoblastic leukemia (B-ALL) that overexpress this protein.

UR - http://www.scopus.com/inward/record.url?scp=84940192707&partnerID=8YFLogxK

U2 - 10.1182/blood-2015-06-650812

DO - 10.1182/blood-2015-06-650812

M3 - Article

AN - SCOPUS:84940192707

SN - 0006-4971

VL - 126

SP - 567

EP - 569

JO - Blood

JF - Blood

IS - 5

ER -

TSLPR: A new CAR in the showroom for B-ALL

Abstract

Access to Document

Other files and links

Fingerprint

Cite this